Minister Bandar Alkhorayef Initiates Construction Of Sudair Pharma Insulin Plant To Boost Local Diabetes Treatment Production

Minister of Industry and Mineral Resources Bandar Alkhorayef has initiated the construction of Sudair Pharma Company's insulin plant in Sudair City for Industry and Businesses. This facility is a key project aimed at boosting diabetes treatment production within Saudi Arabia. It aligns with the broader strategy to enhance pharmaceutical security and achieve self-sufficiency in healthcare.

The plant's establishment is crucial due to the high demand for insulin, with around 700,000 patients in Saudi Arabia needing this medication. The facility will produce over 15 million insulin pens annually, meeting the needs of more than 500,000 patients in its first year. This output represents 70% of the total demand for insulin within the Kingdom.

Saudi Arabia aims to localize 85% of its insulin requirements, valued at approximately SAR1.3 billion each year. This initiative positions the Kingdom as a regional leader in producing advanced pharmaceutical products. The localisation effort is supported by strategic partnerships between government bodies and major global pharmaceutical firms.

Collaborations have been established with renowned companies such as Sanofi from France, working alongside Sudair Pharmaceutical. Additionally, agreements involve the Novo Nordisk alliance and Lifera, a company owned by the Public Investment Fund (PIF). These partnerships are pivotal in ensuring a steady supply of insulin within Saudi Arabia.

The new plant will significantly reduce reliance on imported insulin amid global supply challenges. By localising production, Sudair Pharma Company aims to ensure continuous availability of this essential medication. This move is part of a broader effort to strengthen healthcare self-sufficiency across the Kingdom.

The Ministry of Industry and Mineral Resources plays a crucial role in supporting these initiatives. By fostering collaborations with international pharmaceutical giants, the ministry ensures that Saudi Arabia remains at the forefront of pharmaceutical advancements.

This development underscores Saudi Arabia's commitment to enhancing its healthcare infrastructure and securing vital medications for its population. As the country continues to invest in local manufacturing capabilities, it sets a precedent for other nations aiming for similar self-reliance in healthcare resources.

With inputs from SPA